author-photo

Aysun Karatas

15

Papers

28

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (9)
Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany. Results from the prospective German Registry CRISP (AIO-TRK-0315)

2019
Show All
- Source
- Cite
- Save
Citations (0)
1428PTesting for and frequency of molecular alterations in patients with advanced NSCLC in Germany. Results from the prospective German registry CRISP (AIO-TRK-0315)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Molecular testing, frequency of molecular alterations and targeted 1st-line treatment of patients with non-small cell lung carcinoma in Germany: First results from the prospective German Registry CRISP (AIO-TRK-0315).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
O-010Cisplatin/5-fluorouracil +/- panitumumab for patients with non-resectable, advanced or metastatic esophageal squamous cell cancer: A randomized phase III AIO/EORTC trial with an extensive biomarker program

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
POWER: An open-label, randomized phase III trial of cisplatin and 5-FU with or without panitumumab (P) for patients (pts) with nonresectable, advanced, or metastatic esophageal squamous cell cancer (ESCC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
MA08.02 Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
P3.01-088 Molecular Testing and First-Line Treatment of Patients with NSCLC. First Results from the German CRISP Study (AIO-TRK-0315)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Therapieabh?ngiges Kosten- und Erl?smanagement

1998 Hno
Show All
- Source
- Cite
- Save
Citations (0)